(PharmaNewsWire.Com, June 23, 2017 ) Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 42, 25, 3, 37 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Small-Cell Lung Cancer.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
4SC AG A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Alchemia Ltd Amgen Inc Andarix Pharmaceuticals Inc Aposense Ltd Aprea AB Astellas Pharma Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bayer AG BeiGene Ltd Beta Pharma Inc BioLineRx Ltd Bionomics Ltd Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp CellAct Pharma GmbH Cellceutix Corp Cerulean Pharma Inc Cornerstone Pharmaceuticals Inc Critical Outcome Technologies Inc CytRx Corp Double Bond Pharmaceutical International AB Eli Lilly and Company F. Hoffmann-La Roche Ltd G1 Therapeutics Inc Genzyme Corp GlaxoSmithKline Plc Horizon Pharma Plc Hutchison MediPharma Ltd Immunomedics Inc Incyte Corp Johnson & Johnson Karyopharm Therapeutics Inc Kolltan Pharmaceuticals Inc Kyowa Hakko Kirin Co Ltd Lindis Biotech GmbH MabVax Therapeutics Holdings Inc MedImmune LLC Medivation Inc Merck & Co Inc MolMed SpA Mologen AG NanoSmart Pharmaceuticals Inc Nektar Therapeutics Nippon Kayaku Co Ltd Novartis AG Omnitura Therapeutics Inc OncoMed Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Oxford BioTherapeutics Ltd Pfizer Inc Pharma Mar SA Polaris Pharmaceuticals Inc Rexahn Pharmaceuticals Inc SciTech Development, LLC Spectrum Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd Sunshine Biopharma Inc Syros Pharmaceuticals Inc Tarveda Therapeutics Inc Tesaro Inc Teva Pharmaceutical Industries Ltd Verastem Inc Vertex Pharmaceuticals Inc Zensun (Shanghai) Sci & Tech Co Ltd
Number of Products under Development for Small-Cell Lung Cancer, H2 2016 21 Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2016 22 Number of Products under Development by Companies, H2 2016 23 Number of Products under Development by Companies, H2 2016 (Contd..1) 24 Number of Products under Development by Companies, H2 2016 (Contd..2) 25 Number of Products under Development by Companies, H2 2016 (Contd..3) 26 Number of Products under Development by Companies, H2 2016 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H2 2016 28 Comparative Analysis by Late Stage Development, H2 2016 29 Comparative Analysis by Clinical Stage Development, H2 2016 30 Comparative Analysis by Early Stage Development, H2 2016 31 Products under Development by Companies, H2 2016 32 Products under Development by Companies, H2 2016 (Contd..1) 33 Products under Development by Companies, H2 2016 (Contd..2) 34 Products under Development by Companies, H2 2016 (Contd..3) 35 Products under Development by Companies, H2 2016 (Contd..4) 36 Products under Development by Companies, H2 2016 (Contd..5) 37 Products under Development by Companies, H2 2016 (Contd..6) 38 Products under Development by Companies, H2 2016 (Contd..7) 39 Products under Investigation by Universities/Institutes, H2 2016 40 Small-Cell Lung Cancer - Pipeline by 4SC AG, H2 2016 41 Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 42 Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016 43 Small-Cell Lung Cancer - Pipeline by Alchemia Ltd, H2 2016 44 Small-Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016 45 Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 46 Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H2 2016 47 Small-Cell Lung Cancer - Pipeline by Aprea AB, H2 2016 48 Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016 49 Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016 50 Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 51 Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2016 52 Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016 53 Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016 54 Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016 55 Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H2 2016 56 Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 57 Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 58 Small-Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016 59 Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016 60 Small-Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016 61 Small-Cell Lung Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 62 Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 63 Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 64 Small-Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016 65 Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 66 Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016 67 Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 68 Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2016 69 Small-Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016 70 Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 71 Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016 72 Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 73 Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2016 74 Small-Cell Lung Cancer - Pipeline by Incyte Corp, H2 2016 75 Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2016 76 Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 77 Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 78 Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 79 Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H2 2016 80 Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 81 Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2016 82 Small-Cell Lung Cancer - Pipeline by Medivation Inc, H2 2016 83 Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2016 84 Small-Cell Lung Cancer - Pipeline by MolMed SpA, H2 2016 85 Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2016 86 Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 87 Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2016 88 Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 89 Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2016 90 Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 91 Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 92 Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 93 Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 94 Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H2 2016 95 Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H2 2016 96 Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 97 Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 98 Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H2 2016 99 Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 100 Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 101 Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 102 Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H2 2016 103 Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2016 104 Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H2 2016 105 Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 106 Small-Cell Lung Cancer - Pipeline by Verastem Inc, H2 2016 107 Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 108 Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 109 Assessment by Monotherapy Products, H2 2016 110 Assessment by Combination Products, H2 2016 111 Number of Products by Stage and Target, H2 2016 113 Number of Products by Stage and Mechanism of Action, H2 2016 120 Number of Products by Stage and Route of Administration, H2 2016 127 Number of Products by Stage and Molecule Type, H2 2016 129 Small-Cell Lung Cancer - Dormant Projects, H2 2016 565 Small-Cell Lung Cancer - Dormant Projects (Contd..1), H2 2016 566 Small-Cell Lung Cancer - Dormant Projects (Contd..2), H2 2016 567 Small-Cell Lung Cancer - Dormant Projects (Contd..3), H2 2016 568 Small-Cell Lung Cancer - Dormant Projects (Contd..4), H2 2016 569 Small-Cell Lung Cancer - Dormant Projects (Contd..5), H2 2016 570 Small-Cell Lung Cancer - Dormant Projects (Contd..6), H2 2016 571 Small-Cell Lung Cancer - Dormant Projects (Contd..7), H2 2016 572 Small-Cell Lung Cancer - Discontinued Products, H2 2016 573 Small-Cell Lung Cancer - Discontinued Products (Contd..1), H2 2016 574
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
